Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

TriPRIL CAR T Cells in Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma in Relapse
Refractory Multiple Myeloma
Multiple Myeloma

Interventions: Drug: TriPRIL CAR T Cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2021-08-25

Last Posted Date: 2024-04-29

Lead Sponsor: Marcela V. Maus, M.D.,Ph.D.

Target Recruit Count: 18

Registration Number: NCT05020444

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Early Phase 1

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Fludarabine
Drug: Cytoxan
Biological: Dual CD33-CLL1 CAR-T cells

First Posted Date: 2021-08-23

Last Posted Date: 2021-08-23

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 32

Registration Number: NCT05016063

Locations: 🇨🇳
Department of Hematology, Xinqiao Hospital, Chongqing, Chongqing, China

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Early Phase 1

Conditions: Multiple Myeloma, Refractory

Interventions: Biological: Anti-BCMA CAR-NK Cells
Drug: Fludarabine
Drug: Cytoxan

First Posted Date: 2021-08-17

Last Posted Date: 2021-11-23

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 27

Registration Number: NCT05008536

Locations: 🇨🇳
Department of Hematology, Xinqiao Hospital, Chongqing, Chongqing, China

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Conditions: Leukemia, Myeloid, Acute

Interventions: Biological: anti-CD33 CAR NK cells
Drug: Fludarabine
Drug: Cytoxan

First Posted Date: 2021-08-17

Last Posted Date: 2022-01-12

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 27

Registration Number: NCT05008575

Locations: 🇨🇳
Department of Hematology, Xinqiao Hospital, Chongqing, Chongqing, China

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Non-hodgkin Lymphoma
Plasma Cell Myeloma
Leukemia, Myeloid, Acute
Leukemia, Lymphoblastic, Acute, L2
Myelodysplastic Syndromes
Leukemia, Lymphoblastic, Acute, L1

Interventions: Drug: Venetoclax
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-08-13

Last Posted Date: 2023-08-01

Lead Sponsor: Melbourne Health

Target Recruit Count: 18

Registration Number: NCT05005299

Locations: 🇦🇺
Melbourne Health, Melbourne, Victoria, Australia

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma
Hepatocellular Cancer
Metastatic Hepatocellular Carcinoma

Interventions: Drug: Cyclophosphamide
Biological: CAR-T cell
Drug: Fludarabine

First Posted Date: 2021-08-13

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT05003895

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Genetic: ALLO-605
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-08-11

Last Posted Date: 2024-06-28

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 6

Registration Number: NCT05000450

Locations: 🇺🇸
St. David's South Austin Medical Center, Austin, Texas, United States
🇺🇸
Sarah Cannon/Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Drug: Clofarabine
Procedure: Hematopoietic Cell Transplantation
Radiation: Total-Body Irradiation
Drug: Treosulfan
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Lumbar Puncture
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Biospecimen Collection

First Posted Date: 2021-08-06

Last Posted Date: 2024-07-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 80

Registration Number: NCT04994808

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Bisantrene Combination for Resistant AML

Phase 2

Recruiting

Conditions: Myelogenous Leukemia, Acute

Interventions: Drug: Bisantrene
Drug: Fludarabine
Drug: Clofarabine

First Posted Date: 2021-08-04

Last Posted Date: 2023-11-28

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 29

Registration Number: NCT04989335

Locations: 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Phase 1

Recruiting

Conditions: Relapsed and/or Refractory B-cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: KITE-363
Biological: KITE-753

First Posted Date: 2021-08-04

Last Posted Date: 2024-12-27

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 114

Registration Number: NCT04989803

Locations: 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy